SCHEMBL20211463

SCHEMBL20211463

CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(O)C(O)C(O)C(O)C(O)C(O)C(O)C(O)CO

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.59
CYP2D6 P10635 2/20 0.59
SPHK1 Q9NYA1 2/20 0.59
GMNN O75496 1/20 0.59
POLB P06746 1/20 0.59
THPO P40225 1/20 0.59
MTOR P42345 1/20 0.59
BLM P54132 1/20 0.59
KDM4E B2RXH2 1/20 0.59
TP53 P04637 1/20 0.59
CYP1A2 P05177 1/20 0.59
CYP3A4 P08684 1/20 0.59
MAPT P10636 1/20 0.59
CETP P11597 1/20 0.59
HTT P42858 1/20 0.59
UBE2N P61088 1/20 0.59
TDP1 Q9NUW8 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.48
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29720590 1.00 LMNA (0.59) LMNACYP2D6SPHK1GMNNPOLB
SCHEMBL31410092 1.00 LMNA (0.59) LMNACYP2D6SPHK1GMNNPOLB
SCHEMBL28559859 0.98 LMNA (0.55) LMNACYP2D6SPHK1GMNNPOLB
SCHEMBL19067994 0.96 LMNA (0.57) LMNACYP2D6SPHK1GMNNPOLB
SCHEMBL2153227 0.93 LMNA (0.61) LMNACYP2D6SPHK1GMNNPOLB
SCHEMBL3194521 0.93 LMNA (0.61) LMNACYP2D6SPHK1GMNNPOLB
SCHEMBL2992148 0.93 LMNA (0.61) LMNACYP2D6SPHK1GMNNPOLB
SCHEMBL28128055 0.93 LMNA (0.61) LMNACYP2D6SPHK1GMNNPOLB
SCHEMBL3169739 0.91 LMNA (0.57) LMNACYP2D6SPHK1GMNNPOLB
SCHEMBL21357933 0.91 LMNA (0.57) LMNACYP2D6SPHK1GMNNPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240101594-A1 STEROIDS AND PROTEIN-CONJUGATES THEREOF REGENERON PHARMACEUTICALS, INC. 2024-03-28 US disclosed
US-11760775-B2 Steroids and protein-conjugates thereof REGENERON PHARMACEUTICALS, INC. 2023-09-19 US disclosed
US-20230035898-A1 CYCLODEXTRIN PROTEIN DRUG CONJUGATES REGENERON PHARMACEUTICALS, INC. 2023-02-02 US disclosed
US-20210040144-A1 STEROIDS AND PROTEIN-CONJUGATES THEREOF REGENERON PHARMACEUTICALS, INC. 2021-02-11 US disclosed
US-10711032-B2 Steroids and protein-conjugates thereof REGENERON PHARMACEUTICALS, INC. (US) 2020-07-14 US disclosed
US-20180333504-A1 CYCLODEXTRIN PROTEIN DRUG CONJUGATES REGENERON PHAMACEUTICALS, INC. 2018-11-22 US disclosed
US-20180155389-A1 STEROIDS AND PROTEIN-CONJUGATES THEREOF REGENERON PHARMACEUTICALS, INC. 2018-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240101594-A1 STEROIDS AND PROTEIN-CONJUGATES THEREOF SERPINA6, NR3C1, NR3C2 LMNA 3616/4885CYP2D6 4445/4885SPHK1 2862/4885
US-20180333504-A1 CYCLODEXTRIN PROTEIN DRUG CONJUGATES SDCBP, DDOST, KRTCAP2 LMNA 3244/4885CYP2D6 2744/4885SPHK1 3427/4885
US-20180155389-A1 STEROIDS AND PROTEIN-CONJUGATES THEREOF SERPINA6, NR3C1, NR3C2 LMNA 3817/4885CYP2D6 4440/4885SPHK1 2835/4885
US-20230035898-A1 CYCLODEXTRIN PROTEIN DRUG CONJUGATES SDCBP, DDOST, KRTCAP2 LMNA 3244/4885CYP2D6 2744/4885SPHK1 3427/4885
US-10711032-B2 Steroids and protein-conjugates thereof SERPINA6, NR3C1, NR3C2 LMNA 3817/4885CYP2D6 4440/4885SPHK1 2835/4885
US-20210040144-A1 STEROIDS AND PROTEIN-CONJUGATES THEREOF SERPINA6, NR3C1, NR3C2 LMNA 3616/4885CYP2D6 4445/4885SPHK1 2862/4885
US-11760775-B2 Steroids and protein-conjugates thereof SERPINA6, NR3C1, NR3C2 LMNA 3616/4885CYP2D6 4445/4885SPHK1 2862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.